Author

L. Santollani

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

K. D. Wittrup· 3 shared D. J. Irvine· 2 shared J. A. Stinson· 2 shared J. R. Palmeri· 2 shared L. R. Duhamel· 2 shared W. Pinney· 2 shared A. Sheen· 1 shared A. Tabet· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

K. D. Wittrup

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Local delivery of cell surface-targeted immunocytokines programs systemic anti-tumor immunity

L. Santollani, Y. J. Zhang, L. Maiorino, J. R. Palmeri, J. A. Stinson, L. R. Duhamel, K. Qureshi, J. R. Suggs, O. T. Porth, W. Pinney, R. Al Msari, K. D. Wittrup, D. J. Irvine

This study develops CD45-targeted immunocytokines that localize to immune cells in tumors and lymph nodes, eradicating both treated and distant tumors in mouse models.

bioRxiv · Jan 3, 2024 · PreprintImmunology

Tregs constrain CD8+ T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapy

J. R. Palmeri, B. M. Lax, J. M. Peters, L. R. Duhamel, J. A. Stinson, L. Santollani, E. A. Lutz, W. Pinney, B. D. Bryson, K. D. Wittrup

The paper shows that inhibiting Tregs enhances CD8+ T cell priming, improving antitumor responses to 4-1BB combination therapy.

bioRxiv · Jan 30, 2023 · PreprintImmunology

Reprogramming brain immunosurveillance with engineered cytokines

A. Tabet, Y. Agarwal, J. Stinson, C. Apra, V. Will, M. Manthey, N. Momin, A. Sheen, M. Murdock, L. Santollani, L.-H. Tsai, I. Chiu, S. E. Lawler, D. J. Irvine, K. D. Wittrup, P. Anikeeva

This study shows engineered cytokines can reprogram brain immunosurveillance by extending their residence time in the brain using alum scaffolds, delaying tumor progression in mouse models.

bioRxiv · Jun 21, 2022 · PreprintBioengineering